Carl June

Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, MD and Baylor College of Medicine in Houston, TX. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells, CAR-Ts. CTL019, the CAR T cell developed in the June laboratory was the first cell and gene therapy to be approved by the US FDA. He has published more than 500 manuscripts and is the recipient of numerous honors, including a lifetime achievement award from the Leukemia and Lymphoma Society.